Concepedia

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> Inhibitor

Le Wang, George Doherty, Andrew S. Judd, Zhi‐Fu Tao, Terkel Hansen, Robin R. Frey, Xiaohong Song, Milan Bruncko, Aaron Kunzer, Xilu Wang,

ACS Medicinal Chemistry Letters · 2020 · 136 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

. A-1331852 has since been used as a critical tool molecule for further exploring BCL-2 family protein biology, while also representing an attractive entry into a drug discovery program.

References

23

Molecular Properties That Influence the Oral Bioavailability of Drug Candidates

Daniel F. Veber, Stephen R. Johnson, Hung‐Yuan Cheng et al. · Journal of Medicinal Chemistry · 2002 · 8.1K citations

, , +15

Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success

Frank Lovering, Jack Bikker, Christine Humblet · Journal of Medicinal Chemistry · 2009 · 4.4K citations

, , +8

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations

, , +14

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

, , +10

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

, , +16